CHIMERIC RECEPTOR POLYPEPTIDES IN COMBINATION WITH TRANS METABOLISM MOLECULES THAT RE-DIRECT GLUCOSE METABOLITES OUT OF THE GLYCOLYSIS PATHWAY AND THERAPEUTIC USES THEREOF
Genetically engineered hematopoietic cells, which express one or more factors that redirect glucose metabolites, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide, a chimeric antigen receptor (CAR) polypeptide, or a TCR polypeptide) capable...
Gespeichert in:
Hauptverfasser: | , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Genetically engineered hematopoietic cells, which express one or more factors that redirect glucose metabolites, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide, a chimeric antigen receptor (CAR) polypeptide, or a TCR polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof. |
---|